Clinical Trial Update: Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study

View source ↗

Summary

An observational study in Portugal is evaluating ofatumumab for relapsing multiple sclerosis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis | Status: RECRUITING